VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DNTHDianthus Therapeutics, Inc.
$86.98$3.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDNTHFinancials

Dianthus Therapeutics, Inc. (DNTH) Income Statement

10Y historyFree accessUpdated daily

Revenue fell from $2.2M in 2024Q3 to $1.2M in 2026Q3 while R&D rose to $45.6M and the operating margin reached -48.3% in 2026Q3 (-244.9% in 2025Q4), indicating costs are scaling far faster than any recurring revenue base.

Income StatementBalance SheetCash FlowRatios

DNTH Income Statement

Annual statement

DNTH Income Statement

Dianthus Therapeutics, Inc. (DNTH) annual income statement — 10-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue2.72M2.04M6.24M2.83M6.42M1.48M00000
Revenue Growth %-11.7%-67.35%120.63%-55.96%334.76%------
Cost of Goods Sold76K000001.98M1.84M875K376K6K
COGS % of Revenue-----------
Gross Profit2.64M2.04M6.24M2.83M6.42M1.48M-1.98M-1.84M-875K-376K-6K
Gross Margin %97.2%100%100%100%100%100%-----
Gross Profit Growth %--67.35%120.63%-55.96%334.76%174.62%-7.32%-110.63%-132.71%-6166.67%-
Operating Expenses238.67M179.97M108.1M51M36.12M14.56M76.72M81.13M59.09M35.35M9.26M
OpEx % of Revenue-8839.34%1733.75%1804.67%562.91%986.59%-----
Selling, General & Admin50.04M34.33M24.99M18.16M6.74M1.96M28.09M23.76M17.75M7.45M3.48M
SG&A % of Revenue-1686.2%400.87%642.57%105.08%132.52%-----
Research & Development188.71M145.64M83.11M32.84M29.38M12.61M48.64M57.37M41.34M27.9M5.78M
R&D % of Revenue-7153.14%1332.88%1162.1%457.83%854.06%-----
Other Operating Expenses00000000000
Operating Income-236.03M-177.93M-101.86M-48.17M-29.7M-13.09M-78.7M-82.97M-59.96M-35.73M-9.27M
Operating Margin %-8683.89%-8739.34%-1633.75%-1704.67%-462.91%-886.59%-----
Operating Income Growth %--74.68%-111.45%-62.17%-127%83.37%5.14%-38.37%-67.84%-285.49%-
EBITDA-235.64M-177.5M-101.45M-47.82M-29.56M-11.07M-76.72M-81.13M-59.09M-35.35M-9.26M
EBITDA Margin %-8669.57%-8718.32%-1627.14%-1692.11%-460.62%-749.73%-----
EBITDA Growth %-68.44%-74.96%-112.16%-61.78%-167.11%85.58%5.43%-37.3%-67.15%-281.68%-
D&A (Non-Cash Add-back)389K428K412K355K147K2.02M1.98M1.84M875K376K6K
EBIT-39.79M-162.34M-84.97M-43.55M-28.48M-13.11M-74.94M-76.77M-57.52M-35.49M-9.27M
Net Interest Income35.22M16.12M17.36M4.76M1.15M100K00000
Interest Income35.22M16.12M17.36M4.76M1.15M100K3.77M02.45M236K0
Interest Expense0000003.77M000163K
Other Income/Expense196.24M15.6M16.89M4.62M1.23M-23K3.77M6.2M2.45M236K-163K
Pretax Income-39.79M-162.34M-84.97M-43.55M-28.48M-13.11M-74.94M-76.77M-57.52M-35.49M-9.43M
Pretax Margin %-1463.83%-7973.33%-1362.77%-1541.22%-443.76%-888.14%-----
Income Tax000000000236K0
Effective Tax Rate %0%0%0%0%0%0%0%0%0%-0.66%0%
Net Income-39.79M-162.34M-84.97M-43.55M-28.48M-13.11M-74.94M-76.77M-57.52M-35.49M-9.43M
Net Margin %-1463.83%-7973.33%-1362.77%-1541.22%-443.76%-888.14%-----
Net Income Growth %68.51%-91.05%-95.08%-52.95%-117.22%82.51%2.39%-33.48%-62.06%-276.32%-
Net Income (Continuing)-39.79M-162.34M-84.97M-43.55M-28.48M-13.11M-74.94M-76.77M-57.52M-35.49M-9.43M
Discontinued Operations00000000000
Minority Interest00000000000
EPS (Diluted)-0.69-4.20-2.55-8.45-7.60-3.82-27.30-33.18-27.62-16.05-4.27
EPS Growth %100.86%-64.71%69.82%-11.18%-98.95%86.01%17.72%-20.13%-72.09%-275.88%-
EPS (Basic)--4.20-2.55-8.45-7.60-3.82-27.30-33.18-27.62-16.05-4.27
Diluted Shares Outstanding57.34M37.79M33.31M5.15M3.75M3.43M2.75M2.31M2.08M2.21M2.21M
Basic Shares Outstanding57.34M37.79M33.31M5.15M3.75M3.43M2.75M2.31M2.08M2.21M2.21M
Dividend Payout Ratio-----------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical-stage cash burn and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Legacy Revenue Wind-Down Continues

Based on reported quarterly figures, DNTH's revenue fell from $2.2M in 2024Q3 to $1.2M in 2026Q3 with year-over-year growth swinging between sharp declines and volatile rebounds, suggesting legacy collaboration income is not recurring.

The revenue series is lumpy and dominated by milestone-type receipts rather than any product or royalty base, so quarterly growth rates carry little information about underlying commercial momentum. The reported 2.1% year-over-year gain in 2026Q3 appears to reflect timing of a single receipt rather than a durable trend. Investors should treat the revenue line as incidental to the investment case and monitor whether it stabilizes or simply reverts to zero.

Operating Losses Scale With R&D Spend

As reported in the income statement, DNTH's R&D expense rose from $18.1M in 2024Q2 to $45.6M in 2026Q3, pushing operating losses to -$58.5M, which indicates operating costs are scaling far faster than any revenue base.

Because revenue is negligible, operating leverage works in reverse: each incremental dollar of clinical spending deepens the operating deficit rather than improving margins. SG&A has grown more modestly, from $6.0M to $14.1M, which suggests the cost base is dominated by program execution rather than overhead. The trajectory implies that any path to breakeven is entirely dependent on future commercial revenue that is not yet visible in the data.

Net Income Distorted by Non-Operating Items

Based on EDBL-style reporting logic applied here, DNTH's 2025Q4 net income of $97.9M against an operating loss of -$69.5M suggests a large non-operating gain that is unrelated to core clinical activity.

The swing from a deep operating loss to positive net income in 2025Q4 appears driven by items below the operating line, such as warrant revaluation, other income, or merger-related accounting, rather than improved operations. Stock-based compensation of $6.0M to $12.7M over the period is also material relative to revenue and merits attention as a non-cash cost. Analysts should strip these items out when assessing the true economic loss per share.

Cash Burn Outpaces Visible Funding

Based on reported figures, DNTH's quarterly operating loss near -$58.5M in 2026Q3 against a reported $51M cash balance suggests the runway may be under one year if burn persists at current levels.

This is an analytical inference from reported figures rather than disclosed guidance, since the latest report provided no runway commentary. The gap between quarterly burn and cash on hand raises the probability of a dilutive financing or partnership event in the near term, which could pressure per-share economics. Investors should monitor financing announcements and any change in R&D trajectory as the key signals.

R&D Dominates a Rising Cost Base

As reported in the income statement, R&D expense of $45.6M in 2026Q3 represents roughly 77% of total operating expenses, indicating that clinical program spending drives nearly all of the cost base.

The expense mix is consistent with a clinical-stage developer running multiple concurrent trials, where enrollment and CRO activity set the cost trajectory. SG&A has been held at a comparatively stable share, which may reflect disciplined overhead management following the reverse merger. Any slowdown in trial execution would likely be visible first in R&D and should be watched as a leading indicator of pipeline timing.

DNTH — Frequently Asked Questions

Quick answers to the most common questions about buying DNTH stock.

What was Dianthus Therapeutics, Inc.'s (DNTH) revenue in 2025?

For fiscal year 2025, Dianthus Therapeutics, Inc. (DNTH) reported total revenue of $2.0M.

Is Dianthus Therapeutics, Inc. (DNTH) profitable?

Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $162.3M for the fiscal year ending 2025.

What is Dianthus Therapeutics, Inc.'s operating profit margin?

Dianthus Therapeutics, Inc. (DNTH) reported an operating income of $-177.9M, resulting in an operating profit margin of -8739.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Dianthus Therapeutics, Inc.'s gross profit and gross margin?

Dianthus Therapeutics, Inc. (DNTH) generated $2.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.